| Original language | English |
|---|---|
| Pages (from-to) | 248-255 |
| Number of pages | 8 |
| Journal | Seminars in Hematology |
| Volume | 55 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2018 |
Keywords
- hemoglobin
- ruxolitinib, adult
- aged
- anemia
- Article
- drug efficacy
- drug response
- female
- high risk patient
- human
- intermediate risk patient
- International Prognostic Scoring System
- leukocyte count
- major clinical study
- male
- multicenter study
- myelofibrosis
- overall survival
- phenotype
- platelet count
- polycythemia vera
- priority journal
- probability
- prognosis
- scoring system
- survival rate
- thrombocythemia
- thrombocytopenia
- validity
Cite this
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎. / Palandri, F.; Palumbo, G.A.; Iurlo, A.; Polverelli, N.; Benevolo, G.; Breccia, M.; Abruzzese, E.; Tiribelli, M.; Bonifacio, M.; Tieghi, A.; Isidori, A.; Martino, B.; Sgherza, N.; D'Adda, M.; Bergamaschi, M.; Crugnola, M.; Cavazzini, F.; Bosi, C.; Binotto, G.; Auteri, G.; Latagliata, R.; Ibatici, A.; Scaffidi, L.; Penna, D.; Cattaneo, D.; Soci, F.; Trawinska, M.; Russo, D.; Cuneo, A.; Semenzato, G.; Di Raimondo, F.; Aversa, F.; Lemoli, R.M.; Heidel, F.; Reggiani, M.L.B.; Bartoletti, D.; Cavo, M.; Catani, L.; Vianelli, N.
In: Seminars in Hematology, Vol. 55, No. 4, 2018, p. 248-255.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎
AU - Palandri, F.
AU - Palumbo, G.A.
AU - Iurlo, A.
AU - Polverelli, N.
AU - Benevolo, G.
AU - Breccia, M.
AU - Abruzzese, E.
AU - Tiribelli, M.
AU - Bonifacio, M.
AU - Tieghi, A.
AU - Isidori, A.
AU - Martino, B.
AU - Sgherza, N.
AU - D'Adda, M.
AU - Bergamaschi, M.
AU - Crugnola, M.
AU - Cavazzini, F.
AU - Bosi, C.
AU - Binotto, G.
AU - Auteri, G.
AU - Latagliata, R.
AU - Ibatici, A.
AU - Scaffidi, L.
AU - Penna, D.
AU - Cattaneo, D.
AU - Soci, F.
AU - Trawinska, M.
AU - Russo, D.
AU - Cuneo, A.
AU - Semenzato, G.
AU - Di Raimondo, F.
AU - Aversa, F.
AU - Lemoli, R.M.
AU - Heidel, F.
AU - Reggiani, M.L.B.
AU - Bartoletti, D.
AU - Cavo, M.
AU - Catani, L.
AU - Vianelli, N.
N1 - cited By 0
PY - 2018
Y1 - 2018
KW - hemoglobin
KW - ruxolitinib, adult
KW - aged
KW - anemia
KW - Article
KW - drug efficacy
KW - drug response
KW - female
KW - high risk patient
KW - human
KW - intermediate risk patient
KW - International Prognostic Scoring System
KW - leukocyte count
KW - major clinical study
KW - male
KW - multicenter study
KW - myelofibrosis
KW - overall survival
KW - phenotype
KW - platelet count
KW - polycythemia vera
KW - priority journal
KW - probability
KW - prognosis
KW - scoring system
KW - survival rate
KW - thrombocythemia
KW - thrombocytopenia
KW - validity
U2 - 10.1053/j.seminhematol.2018.05.013
DO - 10.1053/j.seminhematol.2018.05.013
M3 - Article
VL - 55
SP - 248
EP - 255
JO - Seminars in Hematology
JF - Seminars in Hematology
SN - 0037-1963
IS - 4
ER -